Article

How Lung Adenocarcinoma Cells Survive Outside the Lungs

Extracellular matrix receptors shield cancer cells from harsh environments.

A new study identified how lung cancer cells can thrive outside the lungs, and eventually spread to the brain.

Lung adenocarcinoma is a lethal form of lung cancer, in which tumor cells often spread to the brain well before diagnosis. Furthermore, it can develop in both non-smokers and smokers. More individuals die of lung cancer annual than breast, colon, and prostate cancers combined.

Often, before an individual is even diagnosed with lung adenocarcinoma, the tumor cells have already spread to the brain. In a study published in Cancer Research, investigators sought to determine how the tumor cells can grow outside the lungs.

The investigators analyzed RNA from patients with adenocarcinoma that was limited to the lungs and in individuals whose cancer had spread.

The results of the study showed that aggressive lung adenocarcinoma cells had a high expression of proteins that allow the cancer cells to survive outside the lungs in small numbers. Furthermore, tumor cells that spread to the brain utilized an extracellular molecule that protected them from the hostile environment.

“These occult lung cancer cells have found a unique way to co-opt the ‘brain microenvironment’ and survive,” said lead investigator Don Nguyen.

According to Nguyen, the study findings have already resulted in a collaboration with a pharmaceutical company to test drugs that target this pathway.

Related Videos
Anthony Perissinotti, PharmD, BCOP, discusses unmet needs and trends in managing chronic lymphocytic leukemia (CLL), with an emphasis on the pivotal role pharmacists play in supporting medication adherence and treatment decisions.
Image Credit: © alenamozhjer - stock.adobe.com
pharmacogenetics testing, adverse drug events, personalized medicine, FDA collaboration, USP partnership, health equity, clinical decision support, laboratory challenges, study design, education, precision medicine, stakeholder perspectives, public comment, Texas Medical Center, DNA double helix
pharmacogenetics challenges, inter-organizational collaboration, dpyd genotype, NCCN guidelines, meta census platform, evidence submission, consensus statements, clinical implementation, pharmacotherapy improvement, collaborative research, pharmacist role, pharmacokinetics focus, clinical topics, genotype-guided therapy, critical thought
Image Credit: © Andrey Popov - stock.adobe.com
Image Credit: © peopleimages.com - stock.adobe.com
TRUST-I and TRUST-II Trials Show Promising Results for Taletrectinib in ROS1+ NSCLC
World Standards Week 2024: US Pharmacopeia’s Achievements and Future Focus in Pharmacy Standards